Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia‐related changes: Post hoc analysis of the QUAZAR AML ‐001 trial

Documenti analoghi

• Combining 5‐azacitidine with the E‐selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia
  di: Anoop K. Enjeti, et al.
  Pubblicazione: (2024)
• Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
  di: Barbora Weinbergerová, et al.
  Pubblicazione: (2024)
• Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission
  di: Ling Jiang, et al.
  Pubblicazione: (2024)
• Characteristics and prognosis of paediatric normal karyotype acute myeloid leukaemia: A NOPHO‐DBH AML study
  di: Morten Krogh Herlin, et al.
  Pubblicazione: (2025)
• Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial ( JCCG AML ‐12)
  di: Tomoya Komori, et al.
  Pubblicazione: (2026)